Accell
Accell Clinical Research is a privately held, full-service CRO founded in 2007 that runs Phase I–IV clinical trials for global pharma and biotech sponsors across Eastern Europe, the Baltics, the Balkans, and Central Asia, with a specialized oncology division (Accell Oncology) and operations hubs in Russia, the USA, and Romania.
- Company typePrivate
- Founded2007
- HeadquartersWarrenton, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Accell does
Accell Clinical Research, LLC is a privately held, full-service Contract Research Organization (CRO) founded in 2007 by Natalia Nayanova and Julia Kondakov, headquartered operationally in St. Petersburg, Russia, with a contractual and legal entity in Culpeper, Virginia (USA) and a 2022-established European operations office in Bucharest, Romania. The company delivers Phase I–IV clinical trial management, functional outsourcing, strategic guidance and trial set-up, and rescue study services to global pharmaceutical and biotechnology sponsors executing trials in Eastern Europe, the Baltic states, the Balkans, the Caucasus, Central Asia, and the EAEU. A specialized sub-brand, Accell Oncology (launched 2018), positions the firm as the only oncology-focused CRO in Eastern Europe and Russia, supported by a network of 150+ oncology sites and 200+ cardiology sites; the company also operates the OncoForum online platform (launched 2019) for organizing virtual advisory boards with oncology key opinion leaders.
Revenue is generated through project-based professional services engagements, with quote-driven, non-publicly-disclosed pricing. Go-to-market is enterprise field sales executed by a Business Development team spread across the USA, UK, Romania, and the Netherlands, supported by heavy presence at industry conferences (ASCO, ESMO, BIO, CPHI, DIA, Nordic Life Science Days, Medidata NEXT). The customer base is concentrated in large global pharmaceutical sponsors and mid-to-large biotechnology companies, with case-study engagements spanning Phase III oncology, cardiology, gastroenterology, and onco-hematology programs. Differentiators include a physician-led team in which ~80% of clinical staff hold MD degrees, demonstrated recruitment rates 3–7x above rest-of-world benchmarks across multiple therapeutic areas, clean inspection records from EMA and Roszdravnadzor, and ICH E6 GCP compliance. Following the 2022 geopolitical events, the company has temporarily suspended new activities in Russia and Ukraine and is repositioning its operational base toward EU-domiciled delivery via Romania and the Syntax for Science partnership in Spain.
Accell firmographics
Firmographics- Name
- Accell
- Legal name
- Accell Clinical Research, LLC
- Website
- https://accellclinical.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Accell Clinical Research is a privately held, full-service CRO founded in 2007 that runs Phase I–IV clinical trials for global pharma and biotech sponsors across Eastern Europe, the Baltics, the Balkans, and Central Asia, with a specialized oncology division (Accell Oncology) and operations hubs in Russia, the USA, and Romania.
- Ownership category
- akta.pro rank
Accell industry classification
Industry- Product category
- Contract Research Organization (Clinical Trial Services)
- NAICS
- Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)
Keywords
Where Accell is headquartered
LocationHeadquarters
- HQ city
- Warrenton
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Accell business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Clinical Research Services: Full-service CRO providing clinical trial management, site selection, regulatory affairs, and operational support for pharmaceutical and biotech sponsors. Project-based professional services across phases I-IV clinical trials.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Accell product offering
Product offeringCore offering
Accell Clinical Research is a full-service Contract Research Organization (CRO) that manages Phase I-IV clinical trials for pharmaceutical and biotech sponsors across Eastern Europe, Russia, and CIS countries. Its core offerings include clinical trial management, functional outsourcing of clinical research staff, strategic guidance and trial set-up (feasibility, site selection, regulatory affairs), and rescue studies for delayed trials. Through its Accell Oncology sub-brand, it operates the only oncology-specialized CRO division in Eastern Europe and Russia, supplemented by the OncoForum online platform for virtual advisory boards with oncology key opinion leaders.
Product overview
Accell Clinical Research is a full-service Contract Research Organization (CRO) that provides clinical trial services across Eastern Europe, Russia, and CIS countries. The company operates through its core service offerings (Clinical Trial Management, Functional Outsourcing, Strategic Guidance & Trial Set-up, and Rescue Studies) and a specialized oncology sub-brand called Accell Oncology. Accell Oncology, launched in 2018, is positioned as the only oncology-specialized CRO in Eastern Europe and Russia. Additionally, the company developed OncoForum, an online platform for organizing virtual oncology advisory boards with key opinion leaders. The company has offices in Russia (Saint Petersburg headquarters), USA (Virginia), and Romania (Bucharest), and maintains active operations across 10+ European and CIS countries.
Differentiator
Problem solved
Functional benefit
Brands
- Accell Oncology: A specialized oncology-focused division of Accell Clinical Research, providing clinical trial services for solid tumors and hematologic tumors in Eastern Europe, Russia, and Ukraine. It also offers an online oncology platform called OncoForum for advisory boards and consultancy services with oncology key opinion leaders.
Products and services
- Clinical Trial Management Full-service clinical trial management from planning to execution, including site management, monitoring, and project coordination, delivered to pharmaceutical and biotech sponsors running Phase I-IV trials.
- Functional Outsourcing Provides clinical operational staff to join client teams as needed, offering flexible resource augmentation for clinical trials, including CRA and project management support on a functional basis.
- Strategic Guidance & Trial Set-up Comprehensive strategic planning services including study feasibility, site selection, regulatory affairs, study documentation development, vendor selection, and investigator meeting organization for pharmaceutical and biotech sponsors.
- Rescue Studies Specialized services to rescue failing clinical trials, including feasibility assessments, country expansion analysis, and functional outsourcing of clinical operational staff for sponsors facing delayed enrollment or operational issues.
- Accell Oncology Specialized oncology-focused clinical trial services division of Accell, including solid tumor and hematologic malignancy trials, advisory boards, and consultancy services with oncology key opinion leaders, supported by a network of 150+ oncology sites.
- OncoForum Online oncology platform for organizing advisory boards and providing consultancy services with oncology key opinion leaders (KOLs), enabling virtual meetings to obtain expert validation on medical and trial design topics for pharmaceutical and biotech clients.
Companies that use Accell
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles2 records
Accell technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Accell partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Syntax for SciencecoreStrategic CRO partnership announced in November 2019 combining Accell's Eastern European expertise with Syntax's Spanish operations - described as 'East meets West' collaboration
- Wuhan National Bio-industry Base (Biolake)minorMeeting with Chinese biotech industrial base delegation in St. Petersburg; Biolake expressed interest in collaboration given Accell's oncology expertise and connections with key opinion leaders in Eastern Europe
- American CRO PartnerminorDuring Boston conference, Julia Kondakov and Maria Mezentseva visited American CRO's office to discuss partnership grounds; companies had collaborated on projects before
- Maximax Pharmaceutical Research Inc. (MPR)minorAccell joined MPR's Global CRO Development Group strategic alliance with other regional CROs (Cromos Pharma, Fortis Clinical Research, Research Development RA) to expand scale, scope and geographic locations
- Cromos PharmaminorPart of MPR CRO Alliance - USA-based CEE CRO partner in the global strategic alliance
- Fortis Clinical Research (India)minorPart of MPR CRO Alliance - India-based CRO partner in the global strategic alliance
- Research Development RA S.A. (South America)minorPart of MPR CRO Alliance - South America-based CRO partner in the global strategic alliance
Scale indicators10 records
Recent moves9 records
Expansion highlights6 records
Accell competitors and assessment
Company assessmentDirect peers
- Cromos Pharma: US-based CRO focused on Central and Eastern Europe with similar regional specialization. Cromos is also a member of the same Maximax Global CRO Alliance with Accell, making it both a partner and the closest direct competitor for CEE oncology and multi-therapeutic trials.
- Worldwide Clinical Trials: Mid-size, full-service global CRO with comparable therapeutic-area focus (oncology, cardiology, CNS) and a similar emphasis on scientific quality and sponsor relationships. Directly competes for mid-cap biotech and large pharma Phase II-IV work.
- Fortis Clinical Research: India-based full-service CRO that is also a partner in the Maximax Global CRO Alliance with Accell. Comparable as a regional-specialist CRO serving global sponsors, with similar cost-arbitrage positioning and Phase I-IV offerings.
Broad incumbents
- Medpace: Mid-to-large full-service CRO with strong therapeutic specialization and reputation for high-quality data. While larger and globally distributed, Medpace is a relevant comparable for Accell's physician-led, therapeutically-aligned operating model.
- IQVIA: Largest global CRO with integrated technology, real-world data, and full Phase I-IV capabilities. Competes with Accell for enterprise pharma trials and increasingly absorbs regional specialists via acquisition, defining the upper-bound competitive threat.
- ICON plc: Global full-service CRO formed via major consolidations (PRA merger), offering biotech and large pharma sponsors end-to-end clinical and post-approval services. Represents the scaled, technology-enabled alternative to Accell's regional specialist model.
- Parexel: Large global CRO with comprehensive Phase I-IV services and strong oncology/biotech franchise post EQT-Goldman take-private. Provides a useful scaled benchmark for what Accell would need to evolve into to compete for multinational trial RFPs.
- Syneos Health: Large CRO and commercialization services provider offering end-to-end clinical development plus commercial solutions. Competitor for large enterprise pharma trial RFPs where Accell might serve as a regional sub-contractor.
Emerging players
- Tigermed (Hangzhou Tigermed): Leading China-based CRO expanding internationally with comparable therapeutic specialization (oncology) and growing EU/US footprint. Represents an emerging non-Western competitor for global sponsors seeking cost-effective, regionalized trial execution.
Regional players
- Clinical Research Services (CRS): European CRO focused on early-phase and bioequivalence studies with strong presence in Germany and broader EU. Relevant as a regional European CRO comparable to Accell's EU expansion strategy post-Russia/Ukraine exit.
Market position
Strengths6 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Accell social profiles
Digital presenceAccell compliance and trust
Trust signalCompliance1 record
Accell financial estimates
Financial estimateRevenue estimate
Valuation estimate
Accell leadership team
Management profileNumber of profiles
Profiles9 records
Accell subsidiaries and ownership
Company hierarchySubsidiaries1 record
Accell funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Accell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Accell
What does Accell do?
Accell Clinical Research is a full-service Contract Research Organization (CRO) that manages Phase I-IV clinical trials for pharmaceutical and biotech sponsors across Eastern Europe, Russia, and CIS countries. Its core offerings include clinical trial management, functional outsourcing of clinical research staff, strategic guidance and trial set-up (feasibility, site selection, regulatory affairs), and rescue studies for delayed trials. Through its Accell Oncology sub-brand, it operates the only oncology-specialized CRO division in Eastern Europe and Russia, supplemented by the OncoForum online platform for virtual advisory boards with oncology key opinion leaders.
Is Accell a public or private company?
Accell is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Accell founded?
Accell was founded in 2007. It employs 11 to 50 people.
Where is Accell based?
Accell is headquartered in Warrenton, United States, in the North America region.
How does Accell make money?
One revenue line is on record: clinical Research Services.
Who are Accell's main competitors?
Direct peers on record are Cromos Pharma, Worldwide Clinical Trials and Fortis Clinical Research. Broad incumbents are Medpace, IQVIA, ICON plc, Parexel and Syneos Health. Tigermed (Hangzhou Tigermed) is listed as an emerging player. Clinical Research Services (CRS) is listed as a regional player.
Does Accell have an API?
No public API is recorded for Accell.
What industry is Accell in?
Accell's product category is Contract Research Organization (Clinical Trial Services). Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.